Decade-Long Study Evaluates Cytogenetic Abnormalities’ Effect on CLL Prognosis

By Andrew Moreno - Last Updated: September 30, 2024

A study conducted at a university-affiliated hematology/oncology hospital assessed patients with chronic lymphocytic leukemia (CLL) for cytogenetic abnormalities, then evaluated the effect of those abnormalities on prognosis. The investigators compared their findings with the current literature, presenting their results at the Society of Hematologic Oncology 2024 Annual Meeting in Houston, Texas.

Advertisement

“According to our findings, the presence of cytogenetic abnormalities has an important role in disease risk determination in accordance with the literature,” wrote the investigators.

The retrospective study involved data from 100 adult patients younger than 80 years who were diagnosed with CLL and followed up at the investigators’ clinic from January 2010 to January 2022. The cohort was 30% female and had a mean age of 67.11 years. The patients had a mean age of 61.32 years at CLL diagnosis.

Cytogenetic abnormalities of any type were present in 56% of the patient cohort. The most common abnormality was 13q14 deletion, which was positive in 40.3% of the patients. 17p deletion was found to be positive in 17% of the patients, 11q deletion in 15.4%, and trisomy 12 in 12.5%. The study found that 17p and 11q deletions were associated with poor prognosis.

Based on their findings, the investigators stressed that “cytogenetic anomaly screening should be performed in every patient before treatment.”

Reference

Gölbaşı M, Ünal A, Özkul Y, et al. Frequency of genetic mutations in patients with chronic lymphocytic leukemia and their effects on survival. Abstract #CLL-168. Presented at the Society of Hematologic Oncology 2024 Annual Meeting; September 4-7, 2024; Houston, Texas.

Advertisement
Advertisement
Advertisement
Editorial Board